- Disability After "Recovery" From
GBS -
Kleopas A. Kleopa, M.D. Neuromuscular
Fellow
Mark J. Brown, M.D. Professor
Department of Neurology
University of Pennsylvania
School of Medicine
Philadelphia, PA
This article was published in "Communicator"
2000
Guillain-Barré syndrome (GBS) is the most common
cause of acute neuromuscular paralysis in developed countries. Most
patients recover and return to productive, independent lives. In a
recent representative survey of 140 GBS patients, 70% made a complete
neurological recovery within a year, 22% could walk but were unable
to run, 8% were unable to walk unaided, and 2% remained bedridden
or ventilator-dependent after a year. Thus, despite the good prognosis
for recovery, GBS can cause long-term disability.
Persisting disability is largely the result of weakness
from the motor nerve injury that occurred during the acute illness.
An estimated 25,000 to 50,000 persons in the United States alone are
experiencing residual effects from the disease. Most research on GBS
has focused on understanding the cause and finding better treatments.
Much less attention has been paid to the long-term disability caused
by GBS. In addition to the previously mentioned residual weakness,
there may be pain, fatigue, psychosocial dysfunction, possible relapses
of the illness, and late progression of weakness.
Pain
Moderate to severe pain is a well-recognized symptom during the course
of acute GBS. For some patients neuropathic pain, consisting of abnormal
painful sensations, may persist after recovery from the disease.
In a recent prospective study of 55 GBS patients followed for up to
24 weeks, pain occurred during the course of the illness in almost
90% of cases. Whereas deep aching back and leg pain were the most
common early on, abnormal painful sensations and myalgic-rheumatic
type pain were observed during the recovery period.
Musculoskeletal pain was common in association with
physiotherapy. Painful abnormal sensations in the extremities tended
to persist after 8 weeks, and were still present in some patients
after 24 weeks. In two cases the pain was severe.
Overall, pain can be effectively relieved with an escalating regimen
of analgesic medications, starting with nonsteroidal anti-inflammatory
drugs or acetaminophen, and if necessary including oral or parenteral
opioids. Even severe pain can be controlled, sometimes with the addition
of patient-controlled analgesia. In a large series of GBS patients
treated for pain, these medications were generally effective, and
no adverse effects on breathing function or narcotic addiction occurred.
Chronic fatigue
Fatigue following GBS is underrecognized by neurologists and rehabilitation
physicians, because attention is directed toward the more objective
weakness and sensory disturbances.
In a recent study of 83 patients recovering from GBS, severe fatigue
was reported as one of the three most disabling symptoms by over 80%.
The incidence of fatigue did not correlate with age, or motor and
sensory residual deficits, but fatigue was more common in women. Fatigue
was unrelated to the time since the acute phase of the GBS, a median
of 5.2 years in this group.
Another study of 123 GBS patients, evaluated 3 to
6 years after the acute illness, concluded that psychosocial functioning,
especially in areas such as sleep and rest, alertness, emotional behavior
and social interaction, was seriously affected. This was true even
when "complete" physical recovery was reached, or only minimal
residual deficits were present. Deconditioning and less engagement
in physical activities were discussed as possible explanations for
persistent fatigue. A supervised training program and low-intensity
aerobic exercise may reduce daily fatigue, with improvements in activities
of daily living and functional capacity. Specific treatments for other
factors associated with fatigue, such as sleep disturbances, pain,
and daytime inactivity, are available.
Psychosocial dysfunction
Reports of long-term psychological sequela after GBS are rare, although
this issue may be a major factor in psychosocial dysfunction of patients
recovering from the disease. Many psychological factors could contribute
to chronic fatigue and social dysfunction, including fear of disability,
inability to cope with physical limitations, and depression following
a major illness.
The role of depression in psychosocial dysfunction
after GBS is not fully understood. The sickness impact profile of
GBS survivors was found to differ from the profile of other patients
with depression. Nevertheless, further study of the long-term psychological
impact of the disease is necessary, and depression should be considered
on an individual basis when appropriate. Both supportive psychotherapy
and/or pharmacologic treatment can be effective.
Post-traumatic stress disorder (PTSD) has been reported
in a patient following severe GBS with paralysis and a prolonged intensive
care stay. The GBS-induced PTSD shared the features of PTSD seen following
other traumatic events. Even such profound psychological problems
following GBS can be treated with supportive psychotherapy and appropriate
medications. They may at least in part be prevented by adequate pain
management and the use of a communication system, such as clear lucid
letter-board in the event of near complete paralysis.
Better understanding, prevention and treatment of
these issues may have a positive impact on the quality of life for
GBS survivors. Moreover, it is important for patients and their families
to know that their psychosocial problems are also experienced by other
patients after GBS.
Recurrence of GBS
Although GBS is thought to be a one-time disease, relapses and chronic
recurrent forms can occur. Patients are often concerned about the
risk of having additional episodes of GBS.
In a study of 220 GBS patients, 15 were found to have
a relapsing course, with one to 4 recurrent episodes. The interval
between episodes ranged from 3 months to 25 years. Antecedent events
such as a viral infection preceded most relapses, and patients presented
each time with the typical clinical and laboratory findings of acute
GBS. All patients had long asymptomatic periods between the episodes.
In a more recent study of 476 patients following GBS,
2.5% experienced a recurrence of the acute illness, with a mean period
of 16 months between the episodes (range 2-47 months). One patient
had three episodes. The authors found no relationship between the
risk of having a recurrent episode and the severity of the first episode.
Furthermore, the severity of the subsequent episode did not correlate
with the intensity of the first episode.
Reaching a correct diagnosis may be challenging in
these cases. Even GBS experts may find it difficult to separate a
"relapsing variant of GBS" from chronic inflammatory demyelinating
polyneuropathy (CIDP), especially early in the course. Recurrent episodes
of true GBS, although rare, may occur following similar preceding
illnesses, and should be treated in the same way as the initial episode.
They respond well to the same established treatment modalities.
Delayed progression
Weakness from GBS reaches its maximum during the first two or three
weeks of the disease. This is the active or acute phase of the illness.
After a plateau period of days or weeks, recovery begins, lasting
between weeks and two years. During this time strength improves steadily.
Strength and sensory function plateau after about two years.
However, many decades after GBS, recovered muscles
once weakened by the disease may again grow weak. This is a slow process
that occurs over years, and may at first escape the patient's notice.
It is likely that this delayed weakness is the effect of the normal
gradual age-related nerve cell loss on muscles that have a reduced
reserve nerve supply from earlier GBS.
The same phenomenon has been observed after poliomyelitis ("post-polio
syndrome") and other forms of acute nerve injury. The incidence
of slowly progressive late weakness in GBS is unknown, but it is rare.
When it does occur, the patient's physician must recognize that the
new weakness of seemingly recovered muscles does not necessarily indicate
a second attack of GBS.
For many patients recovering from GBS, residual motor
or sensory deficits may be only one aspect of the long consequences
of the disease. Other issues described here may have a considerable
impact on their quality of life. Effective treatments are available
for most of these problems.
References available on request. Contact Dr. Kleopa
at: kleopa@mail.med.upenn.edu
Please note:
Information presented in the GBS Newsletter is intended for general
educational purposes only and should not be construed as advising
on diagnosis or treatment of the Guillain-Barré Syndrome or
any other medical condition. Please see the Disclaimer for more information.
Use of this website signifies an acceptance of the
Terms of Use above. No responsibility is taken for any errors, omissions
or misinterpretations. These pages should be used for information
only and you are strongly advised to seek professional help particular
to your circumstances. © Copyright 2001-2004.